Advertisement

Consensus recommendations for the diagnosis and treatment of primary progressive multiple sclerosis in Latin America

Published:August 01, 2018DOI:https://doi.org/10.1016/j.jns.2018.07.024

      Highlights

      • 17 experts from LATAM carry out a consensus recommendation on the diagnosis and treatment of PPMS patients in LATAM.
      • The the 2017 McDonald criteria should be used for diagnosis but exclusion of regional diseases is strongly recommended
      • Specific considerations should be taken regarding immunotherapy treatments used in MS due to the scarce evidence available
      • A general approach that considers symptomatic treatment and rehabilitation should be performed to improve their status

      Abstract

      Despite the availability of a large amount of information regarding the management and care of relapsing remitting multiple sclerosis (RRMS) patients, there is scant information about recommendations on how to care for primary progressive MS (PPMS) patients. The objective of this study was to review how PPMS patients should be assessed and cared for in Latin America (LATAM).

      Methods

      A panel of neurology experts from LATAM dedicated to the diagnosis and care of MS patients gathered virtually during 2017 and 2018 to carry out a consensus recommendation on the diagnosis and treatment of PPMS patients in LATAM. To achieve consensus, the methodology of “formal consensus-RAND/UCLA method” was used.

      Results

      Recommendations focused on disease management, and specific and symptomatic disease treatment were determined. The main consensus was that the 2017 McDonald criteria should be used for diagnosis but that the exclusion of regional diseases is strongly recommended; that specific considerations should be taken regarding immunotherapy treatments used in MS due to the scarce evidence available; and that a general approach that considers symptomatic treatment and rehabilitation should be performed in affected patients to improve their status.

      Conclusions

      The recommendations of these consensus guidelines attempt to optimize the health care and management of PPMS patients in LATAM.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Noseworthy J.H.
        • Lucchinetti C.
        • Rodriguez M.
        • Weinshenker B.G.
        Multiple sclerosis.
        N. Engl. J. Med. 2000; 343: 938-952
        • Trapp B.D.
        • Peterson J.
        • Ransohoff R.M.
        • Rudick R.
        • Mork S.
        • Bo L.
        Axonal transection in the lesions of multiple sclerosis.
        N. Engl. J. Med. 1998; 338: 278-285
        • Kremenchutzky M.
        • Rice G.P.
        • Baskerville J.
        • Wingerchuk D.M.
        • Ebers G.C.
        The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease.
        Brain. 2006; 129: 584-594
        • Miller D.
        • Barkhof F.
        • Montalban X.
        • Thompson A.
        • Filippi M.
        Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis.
        Lancet Neurol. 2005; 4: 281-288
        • Lublin F.D.
        • Reingold S.C.
        Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.
        Neurology. 1996; 46: 907-911
        • Lublin F.D.
        • Reingold S.C.
        • Cohen J.A.
        • Cutter G.R.
        • Sorensen P.S.
        • Thompson A.J.
        • Wolinsky J.S.
        • Balcer L.J.
        • Banwell B.
        • Barkhof F.
        • et al.
        Defining the clinical course of multiple sclerosis: the 2013 revisions.
        Neurology. 2014; 83: 278-286
        • Rice C.M.
        • Cottrell D.
        • Wilkins A.
        • Scolding N.J.
        Primary progressive multiple sclerosis: progress and challenges.
        J. Neurol. Neurosurg. Psychiatry. 2013; 84: 1100-1106
        • Ontaneda D.
        • Thompson A.J.
        • Fox R.J.
        • Cohen J.A.
        Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function.
        Lancet. 2017; 389: 1357-1366
        • Ontaneda D.
        • Cohen J.A.
        • Amato M.P.
        Clinical outcome measures for progressive MS trials.
        Mult. Scler. 2017; 23: 1627-1635
        • Moccia M.
        • de Stefano N.
        • Barkhof F.
        Imaging outcome measures for progressive multiple sclerosis trials.
        Mult. Scler. 2017; 23: 1614-1626
        • Bell B.G.
        • Spencer R.
        • Avery A.J.
        • Campbell S.M.
        Tools for measuring patient safety in primary care settings using the RAND/UCLA appropriateness method.
        BMC Fam. Pract. 2014; 15: 110
        • Santori G.
        • Fontana I.
        • Valente R.
        • Ghirelli R.
        • Valente U.
        Application of the RAND/UCLA Appropriateness Method to evaluate an information system for kidney/pancreas transplantation in adult recipients.
        Transplant. Proc. 2008; 40: 2021-2023
        • Antel J.
        • Antel S.
        • Caramanos Z.
        • Arnold D.L.
        • Kuhlmann T.
        Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?.
        Acta Neuropathol. 2012; 123: 627-638
        • Stevenson V.L.
        • Miller D.H.
        • Rovaris M.
        • Barkhof F.
        • Brochet B.
        • Dousset V.
        • Dousset V.
        • Filippi M.
        • Montalban X.
        • Polman C.H.
        • et al.
        Primary and transitional progressive MS: a clinical and MRI cross-sectional study.
        Neurology. 1999; 52: 839-845
        • Cottrell D.A.
        • Kremenchutzky M.
        • Rice G.P.
        • Koopman W.J.
        • Hader W.
        • Baskerville J.
        • Ebers G.C.
        The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis.
        Brain. 1999; 122: 625-639
        • Rojas J.I.
        • Romano M.
        • Patrucco L.
        • Cristiano E.
        A systematic review about the epidemiology of primary progressive multiple sclerosis in Latin America and the Caribbean.
        Mult. Scler. Relat. Disord. 2018; 22: 1-7
        • Polman C.H.
        • Reingold S.C.
        • Banwell B.
        • Clanet M.
        • Cohen J.A.
        • Filippi M.
        • Fujihara K.
        • Havrdova E.
        • Hutchinson M.
        • Kappos L.
        • et al.
        Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.
        Ann. Neurol. 2011; 69: 292-302
        • Thompson A.J.
        • Banwell B.L.
        • Barkhof F.
        • Carroll W.M.
        • Coetzee T.
        • Comi G.
        • Correale J.
        • Fazekas F.
        • Filippi M.
        • Freedman M.S.
        • et al.
        Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
        Lancet Neurol. 2018; 17: 162-173
        • Rocha A.J.
        • Littig I.A.
        • Nunes R.H.
        • Tilbery C.P.
        Central nervous system infectious diseases mimicking multiple sclerosis: recognizing distinguishable features using MRI.
        Arq. Neuropsiquiatr. 2013; 71: 738-746
        • Miller D.H.
        • Weinshenker B.G.
        • Filippi M.
        • Banwell B.L.
        • Cohen J.A.
        • Freedman M.S.
        • Galetta S.L.
        • Hutchinson M.
        • Johnson R.T.
        • Kappos L.
        • et al.
        Differential diagnosis of suspected multiple sclerosis: a consensus approach.
        Mult. Scler. 2008; 14: 1157-1174
        • Brinar V.V.
        • Habek M.
        Rare infections mimicking MS.
        Clin. Neurol. Neurosurg. 2010; 112: 625-628
        • Thompson H.
        • Thakur K.
        Infections of the central nervous system in returning travelers and immigrants.
        Curr. Infect. Dis. Rep. 2017; 19: 45
        • Yata S.
        • Ogawa T.
        • Sugihara S.
        • Matsusue E.
        • Fujii S.
        • Kinoshita T.
        HTLV-I carrier with unusual brain MR imaging findings.
        Neuroradiology. 2004; 46: 755-758
        • Rovira A.
        • Wattjes M.P.
        • Tintore M.
        • Tur C.
        • Yousry T.A.
        • Sormani M.P.
        • De Stefano N.
        • Filippi M.
        • Auger C.
        • Rocca M.A.
        • et al.
        Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process.
        Nat. Rev. Neurol. 2015; 11: 471-482
        • Wattjes M.P.
        • Rovira A.
        • Miller D.
        • Yousry T.A.
        • Sormani M.P.
        • de Stefano M.P.
        • Tintore M.
        • Auger C.
        • Tur C.
        • Filippi M.
        • et al.
        Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.
        Nat. Rev. Neurol. 2015; 11: 597-606
        • Bot J.C.
        • Barkhof F.
        • Polman C.H.
        • Nijeholt GJ Lycklama A.
        • de Groot V.
        • Bergers E.
        • Ader H.J.
        • Castelijns J.A.
        Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination.
        Neurology. 2004; 62: 226-233
        • Okuda D.T.
        • Mowry E.M.
        • Cree B.A.
        • Crabtree E.C.
        • Goodin D.S.
        • Waubant E.
        • Pelletier D.
        Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome.
        Neurology. 2011; 76: 686-692
        • Freedman M.S.
        • Selchen D.
        • Arnold D.L.
        • Prat A.
        • Banwell B.
        • Yeung M.
        • Morgenthau D.
        • Lapierre Y.
        Canadian Multiple Sclerosis Working G: treatment optimization in MS: Canadian MS Working Group updated recommendations.
        Can. J. Neurol. Sci. 2013; 40: 307-323
        • Confavreux C.
        • Vukusic S.
        • Moreau T.
        • Adeleine P.
        Relapses and progression of disability in multiple sclerosis.
        N. Engl. J. Med. 2000; 343: 1430-1438
        • Kurtzke J.F.
        Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).
        Neurology. 1983; 33: 1444-1452
        • Fischer J.S.
        • Rudick R.A.
        • Cutter G.R.
        • Reingold S.C.
        The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force.
        Mult. Scler. 1999; 5: 244-250
        • Kaufman M.
        • Moyer D.
        • Norton J.
        The significant change for the Timed 25-foot Walk in the multiple sclerosis functional composite.
        Mult. Scler. 2000; 6: 286-290
        • Rio J.
        • Auger C.
        • Rovira A.
        MR imaging in monitoring and predicting treatment response in multiple sclerosis.
        Neuroimaging Clin. N. Am. 2017; 27: 277-287
        • Hawker K.
        • O'Connor P.
        • Freedman M.S.
        • Calabresi P.A.
        • Antel J.
        • Simon J.
        • Hauser S.
        • Waubant E.
        • Vollmer T.
        • Panitch H.
        • et al.
        Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.
        Ann. Neurol. 2009; 66: 460-471
        • Chataway J.
        Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS - YES.
        Mult. Scler. 2017; 23: 505-506
        • Wolinsky J.S.
        • Narayana P.A.
        • O'Connor P.
        • Coyle P.K.
        • Ford C.
        • Johnson K.
        • Miller A.
        • Pardo L.
        • Kadosh S.
        • Ladkani D.
        • et al.
        Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.
        Ann. Neurol. 2007; 61: 14-24
        • Lublin F.
        • Miller D.H.
        • Freedman M.S.
        • Cree B.A.C.
        • Wolinsky J.S.
        • Weiner H.
        • Lubetzki C.
        • Hartung H.P.
        • Montalban X.
        • Uitdehaag B.M.J.
        • et al.
        Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
        Lancet. 2016; 387: 1075-1084
        • Montalban X.
        • Hauser S.L.
        • Kappos L.
        • Arnold D.L.
        • Bar-Or A.
        • Comi G.
        • de Seze J.
        • Giovannoni G.
        • Hartung H.P.
        • Hemmer B.
        • et al.
        Ocrelizumab versus placebo in primary progressive multiple sclerosis.
        N. Engl. J. Med. 2017; 376: 209-220
        • Rice G.P.
        • Filippi M.
        • Comi G.
        Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group.
        Neurology. 2000; 54: 1145-1155
        • Ontaneda D.
        • Fox R.J.
        • Chataway J.
        Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.
        Lancet Neurol. 2015; 14: 208-223
        • Zajicek J.
        • Ball S.
        • Wright D.
        • Vickery J.
        • Nunn A.
        • Miller D.
        • Cano M.G.
        • McManus D.
        • Mallik S.
        • Hobart J.
        • et al.
        Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.
        Lancet Neurol. 2013; 12: 857-865
        • Veauthier C.
        • Hasselmann H.
        • Gold S.M.
        • Paul F.
        The Berlin Treatment Algorithm: recommendations for tailored innovative therapeutic strategies for multiple sclerosis-related fatigue.
        EPMA J. 2016; 7: 25
        • Berger J.R.
        • Pocoski J.
        • Preblick R.
        • Boklage S.
        Fatigue heralding multiple sclerosis.
        Mult. Scler. 2013; 19: 1526-1532
        • Thompson A.J.
        • Toosy A.T.
        • Ciccarelli O.
        Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions.
        Lancet Neurol. 2010; 9: 1182-1199
        • Khan F.
        • Amatya B.
        • Turner-Stokes L.
        Symptomatic therapy and rehabilitation in primary progressive multiple sclerosis.
        Neurol. Res. Int. 2011; 2011: 740505
        • Feinstein A.
        • Freeman J.
        • Lo A.C.
        Treatment of progressive multiple sclerosis: what works, what does not, and what is needed.
        Lancet Neurol. 2015; 14: 194-207
        • Gironi M.
        • Martinelli-Boneschi F.
        • Sacerdote P.
        • Solaro C.
        • Zaffaroni M.
        • Cavarretta R.
        • Moiola L.
        • Bucello S.
        • Radaelli M.
        • Pilato V.
        • et al.
        A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis.
        Mult. Scler. 2008; 14: 1076-1083
        • Novotna A.
        • Mares J.
        • Ratcliffe S.
        • Novakova I.
        • Vachova M.
        • Zapletalova O.
        • Gasperini C.
        • Pozzilli C.
        • Cefaro L.
        • Comi G.
        • et al.
        A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex((R)) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.
        Eur. J. Neurol. 2011; 18: 1122-1131
        • Nicholas R.S.
        • Friede T.
        • Hollis S.
        • Young C.A.
        Anticholinergics for urinary symptoms in multiple sclerosis.
        Cochrane Database Syst. Rev. 2009; 1CD004193
        • Duthie J.B.
        • Vincent M.
        • Herbison G.P.
        • Wilson D.I.
        • Wilson D.
        Botulinum toxin injections for adults with overactive bladder syndrome.
        Cochrane Database Syst. Rev. 2011; 12CD005493
        • Dasgupta R.
        • Wiseman O.J.
        • Kanabar G.
        • Fowler C.J.
        • Mikol D.
        Efficacy of sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis.
        J. Urol. 2004; 171 (discussion 1193): 1189-1193
        • Ehde D.M.
        • Osborne T.L.
        • Jensen M.P.
        Chronic pain in persons with multiple sclerosis.
        Phys. Med. Rehabil. Clin. N. Am. 2005; 16: 503-512
        • Houtchens M.K.
        • Richert J.R.
        • Sami A.
        • Rose J.W.
        Open label gabapentin treatment for pain in multiple sclerosis.
        Mult. Scler. 1997; 3: 250-253
        • Rog D.J.
        • Nurmikko T.J.
        • Friede T.
        • Young C.A.
        Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.
        Neurology. 2005; 65: 812-819
        • Patten S.B.
        • Beck C.A.
        • Williams J.V.
        • Barbui C.
        • Metz L.M.
        Major depression in multiple sclerosis: a population-based perspective.
        Neurology. 2003; 61: 1524-1527
        • Hopko D.R.
        • Lejuez C.W.
        • Ruggiero K.J.
        • Eifert G.H.
        Contemporary behavioral activation treatments for depression: procedures, principles, and progress.
        Clin. Psychol. Rev. 2003; 23: 699-717
        • Amato M.P.
        • Razzolini L.
        • Goretti B.
        • Stromillo M.L.
        • Rossi F.
        • Giorgio A.
        • Hakiki B.
        • Giannini M.
        • Pasto L.
        • Portaccio E.
        • et al.
        Cognitive reserve and cortical atrophy in multiple sclerosis: a longitudinal study.
        Neurology. 2013; 80: 1728-1733
        • Plohmann A.M.
        • Kappos L.
        • Ammann W.
        • Thordai A.
        • Wittwer A.
        • Huber S.
        • Bellaiche Y.
        • Lechner-Scott J.
        Computer assisted retraining of attentional impairments in patients with multiple sclerosis.
        J. Neurol. Neurosurg. Psychiatry. 1998; 64: 455-462
        • Khan F.
        • Pallant J.F.
        • Turner-Stokes L.
        Use of goal attainment scaling in inpatient rehabilitation for persons with multiple sclerosis.
        Arch. Phys. Med. Rehabil. 2008; 89: 652-659
        • Turner-Stokes L.
        • Sykes N.
        • Silber E.
        • Guideline Development G.
        Long-term neurological conditions: management at the interface between neurology, rehabilitation and palliative care.
        Clin. Med. (Lond). 2008; 8: 186-191
      1. Multiple Sclerosis: Management of Multiple Sclerosis in Primary and Secondary Care. edn. London; 2014.

        • Cristiano E.
        • Rojas J.
        • Romano M.
        • Frider N.
        • Machnicki G.
        • Giunta D.
        • Calegaro D.
        • Corona T.
        • Flores J.
        • Gracia F.
        • et al.
        The epidemiology of multiple sclerosis in Latin America and the Caribbean: a systematic review.
        Mult. Scler. 2013; 19: 844-854
        • Montalban X.
        Overview of European pilot study of interferon beta-Ib in primary progressive multiple sclerosis.
        Mult. Scler. 2004; 10 (S62; discussion 62-64)
        • Leary S.M.
        • Miller D.H.
        • Stevenson V.L.
        • Brex P.A.
        • Chard D.T.
        • Thompson A.J.
        Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.
        Neurology. 2003; 60: 44-51